6351 - Heart Diseases: Drugs (Answered)

Jim Shannon
To ask the Secretary of State for Health, if he will take steps to make omega 3 available on prescription to reduce heart disease.

George Freeman

Prescribers can prescribe any product they consider clinically appropriate for the treatment of their patients within medicines legislation, unless that product appears on the list of specific exclusions published under the General Medical Services Contracts regulations.

6107 - National Institute for Health and Care Excellence: Meetings (Answered)

Greg Mulholland
To ask the Secretary of State for Health, when he expects NICE to publish the minutes of the Highly Specialised Technologies Evaluation meeting held on 17 March 2015.

George Freeman

The National Institute for Health and Care Excellence has advised that it expects to publish the minutes of the Highly Specialised Technologies evaluation meeting held on 17 March 2015 on its website by 17 July 2015.

5853 - Medicine: Research (Answered)

Stephen McPartland
To ask the Secretary of State for Business, Innovation and Skills, what assessment he has made of the benefits of supporting medical research and development to the (a) UK science sector, (b) NHS and (c) economy.

George Freeman

6053 - Thromboembolism: Drugs (Answered)

Luciana Berger
To ask the Secretary of State for Health, pursuant to the Answer of 7 July 2015 to Question 5418, for what reasons the report of the review of the use of the drug alteplase was not published at the start of 2015 as originally planned.

George Freeman

5890 - Depressive Illnesses: Roaccutane (Answered)

Jim Shannon
To ask the Secretary of State for Health, what discussions he has had with clinical and pharmaceutical bodies on alleged links between the acne drug roaccutane and depression.

George Freeman

The Medicines and Healthcare products Regulatory Agency has met with various stakeholders regarding the possible link between Roaccutane (isotretinoin) and psychiatric disorders including depression since the late 1990’s.

5888 - Cancer: Drugs (Answered)

Jim Shannon
To ask the Secretary of State for Health, what plans NHS England has to make biphosphorates available as a treatment to prevent breast cancer spreading into bones.

George Freeman

Clinicians are able to prescribe bisphosphonates for the prevention of breast cancer where there is a clinical need.

NHS England’s breast cancer clinical reference group has highlighted bisphosphonates as a key issue for potential improvement in survival outcomes in its draft service specification for breast cancer.

5727 - Dementia: Research (Answered)

Edward Argar
To ask the Secretary of State for Health, how much his Department has provided for research into dementia (a) in cash terms, (b) in real terms, (c) as a proportion of the total research and development budget of his Department in each year since 2005.

George Freeman

5933 - Blood: Screening (Answered)

Jim Shannon
To ask the Secretary of State for Health, if he will take steps to make the HemoLink device for taking blood samples available for use in the NHS.

George Freeman

Manufacturers of medical devices have to obtain a CE mark before their products can be made available on the European Union market. The HemoLink device has not yet received a CE mark and therefore cannot be used as a medical device in the European Union. Decisions on the use of particular products that are CE marked are a matter for individual healthcare providers.

6373 - Cancer: Drugs (Answered)

Mr Jamie Reed
To ask the Secretary of State for Health, what estimate his Department has made of the number of people likely to have been prescribed treatments in 2015-16 which has been removed from the National Cancer Drugs Fund list.

George Freeman

We have made no such estimate.

6343 - Morquio Syndrome: Drugs (Answered)

Greg Mulholland
To ask the Secretary of State for Health, what assessment he has made of the compatibility with paragraph 9 of Article 3 of the EU directive on the transparency of measures regulating the prices of medicinal products for human use of NHS England's decision not to respond to BioMarin's pricing offer for Vimizim in October 2014.

George Freeman

Pages